Akums Drugs & Pharmaceuticals Limited reported a strong financial performance for the second quarter of FY27, with consolidated profit after tax (PAT) increasing 168% year-on-year (YoY) to \u20b9115 crore, compared with \u20b943 crore in Q2 FY26.<\/p>\n\n\n\n
The pharmaceutical contract development and manufacturing organisation (CDMO) reported consolidated revenue of \u20b91,342 crore for the quarter ended September 30, 2026, registering a growth of 31.9% against \u20b91,018 crore in the corresponding quarter of the previous financial year.<\/p>\n\n\n\n
The company’s operating performance also improved significantly, with EBITDA more than doubling to \u20b9195 crore from \u20b994 crore a year ago. EBITDA margin expanded to 14.5% from 9.3% in Q2 FY26.<\/p>\n\n\n\n
The growth was primarily supported by the company’s CDMO business, which continued to benefit from customer demand, higher volumes and improved operating performance.<\/p>\n\n\n\n
Consolidated Performance \u2013 Q2 FY27<\/strong><\/p>\n\n\n\n First-Half Performance \u2013 H1 FY27<\/strong><\/p>\n\n\n\n Akums’ contract development and manufacturing business remained the primary contributor to its quarterly performance.<\/p>\n\n\n\n CDMO revenue increased 38.6% YoY to \u20b91,115 crore in Q2 FY27, compared with \u20b9804 crore in the corresponding quarter last year. The segment contributed approximately 83% of the company’s consolidated revenue.<\/p>\n\n\n\n CDMO EBITDA also nearly doubled to \u20b9168 crore from \u20b984 crore in Q2 FY26. Its EBITDA margin improved to 15.1% from 10.5% a year ago.<\/p>\n\n\n\n The company attributed the improvement to healthy customer demand, double-digit volume growth, better capacity utilisation and improved operating performance.<\/p>\n\n\n\n During the quarter, Akums expanded its manufacturing presence beyond pharmaceuticals by acquiring Oriflame India’s manufacturing business for \u20b956 crore through its wholly owned subsidiary, Pure & Cure Healthcare Private Limited.<\/p>\n\n\n\n The transaction includes two manufacturing facilities located in Roorkee, Uttarakhand, and Noida, Uttar Pradesh, along with a leased warehouse in Noida.<\/p>\n\n\n\n The acquisition marks Akums’ entry into colour cosmetics manufacturing and provides an opportunity to expand its capabilities across skincare, wellness and beauty products.<\/p>\n\n\n\n The company also reported developments across its other business operations. Its API business continued to face challenges, with API revenue declining 35.3% YoY to \u20b929 crore during the quarter.<\/p>\n\n\n\n Meanwhile, Akums is working to expand its international CDMO presence. According to management commentary, the company has a pipeline of more than 30 products for European markets.<\/p>\n\n\n\n Its Zambia initiative is expected to begin commercial supplies from India in Q4 FY27, with revenue contribution anticipated from Q1 FY28.<\/p>\n\n\n\n Akums Drugs & Pharmaceuticals delivered strong year-on-year growth in Q2 FY27, with revenue increasing 31.9% and net profit rising 168%. Improved CDMO performance, higher EBITDA and expansion into colour cosmetics manufacturing were among the key developments during the quarter.<\/p>\n\n\n\n The improvement in operating margins and growth in the CDMO business were important contributors to the company’s financial performance.<\/p>\n\n\n\n\n
\n
CDMO Business Remains the Key Growth Driver<\/h2>\n\n\n\n
Akums Expands into Colour Cosmetics Manufacturing<\/h2>\n\n\n\n
API Business and International Expansion<\/h2>\n\n\n\n
Conclusion<\/h2>\n\n\n\n